Search results for "R2"

showing 10 items of 285 documents

Expression Levels and Clinical-Pathological Correlations of HER2/neu in Primary and Metastatic Human Breast Cancer

2005

In this retrospective study we assessed the expression of the HER2/neu oncogene product in a series of 574 consecutive breast cancer cases, all recruited at the Maurizio Ascoli Cancer Center of Civico Hospital, in Palermo, between January 1998 and June 2003. The HER2/neu expression was evaluated using immunohistochemistry and scored from 0 to +3 as per FDA recommendations. The HER2/neu expression levels were related to the clinical-pathological features of the disease, including tumor size, nodal and menopausal status, estrogen and progesterone receptors, and hormonal or chemotherapeutic treatment. In 108 patients with a follow-up period of 3 years or more, the HER2/neu expression was also …

AdultOncologymedicine.medical_specialtyTime FactorsReceptor ErbB-2medicine.drug_classBreast NeoplasmsDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular BiologyHER2/neuBreast cancerHistory and Philosophy of ScienceInternal medicineBiomarkers TumormedicineHumansNeoplasm Metastasisskin and connective tissue diseasesPathologicalIn Situ Hybridization FluorescenceAgedRetrospective StudiesbiologyOncogenebusiness.industryGeneral NeuroscienceCancerRetrospective cohort studyMiddle Agedmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticTreatment OutcomeEstrogenLymphatic Metastasisbiology.proteinImmunohistochemistryFemalebusinessAnnals of the New York Academy of Sciences
researchProduct

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.

2010

Background: To analyse the discriminative impact of osteopontin (OPN) and activated leukocyte cell adhesion molecule (ALCAM), combined with human epidermal growth factor 2 (HER2) and oestrogen receptor (ER) in breast cancer. Methods: Osteopontin, ALCAM, HER2 and ER mRNA expression in breast cancer tissues of 481 patients were analysed (mRNA microarray analysis, kinetic RT–PCR). Hierarchical clustering was performed in training cohort A (N=100, adjuvant treatment) and validation cohorts B (N=200, no adjuvant treatment, low-risk) and C (N=181, adjuvant treatment, high-risk). Results: Negative/low ER and HER2, high OPN and low ALCAM mRNA expression helped to identify patients at particularly h…

AdultRiskCancer ResearchosteopontinReceptor ErbB-2Eukaryotic Initiation Factor-3discriminative markersBreast NeoplasmsDisease-Free SurvivalHER2 and ER-negative breast cancerBreast cancerActivated-Leukocyte Cell Adhesion MoleculemedicineCluster AnalysisHumansOsteopontinRNA MessengerReceptorskin and connective tissue diseasesMolecular DiagnosticsALCAMALCAMAgedOligonucleotide Array Sequence AnalysisbiologyCell adhesion moleculeDecision TreesActivated-Leukocyte Cell Adhesion MoleculeCancerMiddle Agedmedicine.diseasePrognosisOncologyReceptors EstrogenImmunologybiology.proteinCancer researchFemaleBreast diseaseBritish journal of cancer
researchProduct

Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help.

2007

Liver or lung metastases usually relapse under chemotherapy. Such life-threatening condition urgently needs new, systemic anticancer compounds, with original and efficient mechanisms of action. In B16 melanoma mice treated with cyclophosphamide, D'Agostini et al. [D'Agostini, C., Pica, F., Febbraro, G., Grelli, S., Chiavaroli, C., Garaci, E., 2005. Antitumour effect of OM-174 and Cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol. 5, 1205-1212.] recently found that OM-174, a chemically defined Toll-like receptor(TLR)2/4 agonist, reduces tumor progression and prolongs survival. Here we review 149 articles concerning molecular mechanisms of TLR2…

AgonistLipopolysaccharidesCyclophosphamidemedicine.drug_classmedicine.medical_treatmentNitric Oxide Synthase Type IIAntineoplastic AgentsApoptosisNitric oxidechemistry.chemical_compoundRecurrenceNeoplasmsMedicineAnimalsHumansPharmacologyChemotherapybusiness.industryTumor Necrosis Factor-alphaCancerDendritic Cellsmedicine.diseaseNeoadjuvant TherapyToll-Like Receptor 2Interleukin-10Toll-Like Receptor 4TLR2Lipid ATreatment OutcomechemistryTumor progressionChemotherapy AdjuvantDrug Resistance NeoplasmEnzyme InductionImmunologyCancer researchBCG VaccineTumor necrosis factor alphaImmunotherapybusinessmedicine.drugSignal TransductionT-Lymphocytes CytotoxicEuropean journal of pharmacology
researchProduct

Selection and characterization of a novel agonistic human recombinant anti-Trail-R2 minibody with anti-leukemic activity

2009

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising natural anticancer therapeutic agent because through its “death receptors”, TRAIL-R1 and TRAIL-R2, it induces apoptosis in many transformed tumor cells, but not in the majority of normal cells. Hence, agonistic compounds directed against TRAIL death receptors have the potential of being excellent cancer therapeutic agents, with minimal cytotoxicity in normal tissues. Here, we report the selection and characterization of a new single-chain fragment variable (scFv) to TRAIL-R2 receptor isolated from a human phage-display library, produced as minibody (MB), and characterized for the in vitro anti-leukemic tumoricid…

Agonistmedicine.drug_classTRAIL; TRAIL-R2; minibody; anticancer therapyImmunologylymphoma; therapy; recombinant antibodyTRAILApoptosislymphomaCHO CellsCricetulusPeptide LibraryTRAIL-R2CricetinaeImmunoglobulin FragmentmedicineAnimalsHumansImmunology and Allergyrecombinant antibodyanticancer therapyReceptorCytotoxicityImmunoglobulin FragmentsPharmacologytherapyLeukemiaChemistryAnimalChinese hamster ovary cellAntibody-Dependent Cell CytotoxicityminibodyApoptosiIn vitroRecombinant ProteinsReceptors TNF-Related Apoptosis-Inducing LigandCHO CellCell cultureApoptosisImmunologyCancer researchTumor necrosis factor alphaCricetuluHuman
researchProduct

Locally nilpotent derivations of rings with roots adjoined

2013

Algebra14L30General MathematicsLocally nilpotent13A5014R2013N15Mathematics
researchProduct

Proper triangular Ga-actions on A^4 are translations

2013

We describe the structure of geometric quotients for proper locally triangulable additve group actions on locally trivial A^3-bundles over a noetherian normal base scheme X defined over a field of characteristic 0. In the case where dim X=1, we show in particular that every such action is a translation with geometric quotient isomorphic to the total space of a vector bundle of rank 2 over X. As a consequence, every proper triangulable Ga-action on the affine four space A^4 over a field of characteristic 0 is a translation with geometric quotient isomorphic to A^3.

Algebraaffine spacesMathematics - Algebraic GeometryAlgebra and Number Theorygeometric quotientFOS: Mathematics14L30; 14R20; 14R25[MATH.MATH-AG]Mathematics [math]/Algebraic Geometry [math.AG]Algebraic Geometry (math.AG)proper additive group actionsMathematics[ MATH.MATH-AG ] Mathematics [math]/Algebraic Geometry [math.AG]
researchProduct

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working grou…

2016

The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the g…

AngiogenesisLeftAngiogenesis Inhibitors030204 cardiovascular system & hematologyVentricular Dysfunction Left0302 clinical medicinetyrosine kinase inhibitorNeoplasmstyrosine kinase inhibitorsVentricular DysfunctionMolecular Targeted TherapyEpidermal growth factor receptorSocieties Medicalangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitorABLbiologyDisease ManagementGeneral MedicineItalyCardiovascular DiseasesSupplement Submission030220 oncology & carcinogenesisangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiology; Cardiomyopathies; Cardiotoxicity; Heart Failure; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Ventricular Dysfunction Left; Disease ManagementPractice Guidelines as TopicCardiologyCardiology and Cardiovascular MedicineCardiomyopathiesmedicine.medical_specialtyCardiologyAntineoplastic AgentsRisk AssessmentQT interval03 medical and health sciencesGrowth factor receptorInternal medicineMedicalmedicineHumansMonitoring PhysiologicHeart FailureCardiotoxicitybusiness.industryCancerHER2/epidermal growth factor receptor 2medicine.diseaseangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Cardiology and Cardiovascular MedicineCardiotoxicityangiogenesis inhibitorHeart failurebiology.proteinbusinessSocietiesJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Role of antiemetic prophylaxis for breast cancer (BC) patients treated with anti-HER2 or anti-VEGF monoclonal antibodies.

2014

e20705 Background: To date the anti-emetic prophylaxis based on the combination of 5HT3-antagonists and corticosteroids is mandatory for high and moderate emetogenic cytotoxic agents. This approach...

Anti vegfCancer Researchbusiness.industrymedicine.drug_classmedicine.diseaseMonoclonal antibodyBreast cancerOncologyCancer researchMedicineAntiemeticAnti her2CytotoxicitybusinessJournal of Clinical Oncology
researchProduct

A new technique for observationally derived boundary conditions for space weather

2018

This research has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 647214). D.H.M. would like to thank STFC and the Leverhulme Trust for their financial support. ARY was supported by STFC consortium grant ST/N000781/1 to the universities of Dundee and Durham. Context.  In recent years, space weather research has focused on developing modelling techniques to predict the arrival time and properties of coronal mass ejections (CMEs) at the Earth. The aim of this paper is to propose a new modelling technique suitable for the next generation of Space Weather predictive tools that is both efficie…

Atmospheric Science010504 meteorology & atmospheric sciencesMHDNDASWeather forecastingFluxFOS: Physical sciencesContext (language use)Space weatherlcsh:QC851-999computer.software_genre01 natural sciencesSolar Corona0103 physical sciencesCMECoronal mass ejectionQB AstronomyAstrophysics::Solar and Stellar AstrophysicsQA MathematicsBoundary value problemQA010303 astronomy & astrophysicsR2CSolar and Stellar Astrophysics (astro-ph.SR)QB0105 earth and related environmental sciencesPhysicssolar CoronaMechanicsMagnetic fluxAstrophysics - Solar and Stellar Astrophysics13. Climate actionSpace and Planetary SciencePhysics::Space Physicslcsh:Meteorology. ClimatologyMagnetohydrodynamicsBDCcomputerJournal of Space Weather and Space Climate
researchProduct

Autocorrelation Metrics to Estimate Soil Moisture Persistence From Satellite Time Series: Application to Semiarid Regions

2021

Satellite-derived soil moisture (SM) products have become an important information source for the study of land surface processes in hydrology and land monitoring. Characterizing and estimating soil memory and persistence from satellite observations is of paramount relevance, and has deep implications in ecology, water management, and climate modeling. In this work, we address the problem of SM persistence estimation from microwave sensors using several autocorrelation metrics that, unlike traditional approaches, build on accurate estimates of the autocorrelation function from nonuniformly sampled time series. We show how the choice of the autocorrelation estimator can have a dramatic impac…

Autocorrelation0211 other engineering and technologiesEstimator02 engineering and technology15. Life on landScatterometer6. Clean waterPhysics::GeophysicsAdvanced Microwave Scanning Radiometer-2 (AMSR2) Advanced Scatterometer (ASCAT) autocorrelation e-folding time Least Absolute Shrinkage and Selection Operator (LASSO) Lomb-Scargle periodogram microwave sensors persistence soil moisture Soil Moisture and Ocean Salinity (SMOS) spatial-temporal13. Climate actionConsistency (statistics)General Earth and Planetary SciencesEnvironmental scienceClimate modelSatelliteElectrical and Electronic EngineeringTransectPersistence (discontinuity)021101 geological & geomatics engineeringRemote sensingIEEE Transactions on Geoscience and Remote Sensing
researchProduct